[The role of PSMA PET-CT in patients with metastatic prostate cancer]. / Die Rolle des PSMA-PET/CT bei Patienten mit metastasiertem Prostatakarzinom.
Urologe A
; 56(11): 1410-1416, 2017 Nov.
Article
em De
| MEDLINE
| ID: mdl-28980045
Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy. In metastatic castration-resistant prostate cancer evidence for its use is not available.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Glutamato Carboxipeptidase II
/
Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada
/
Antígenos de Superfície
Tipo de estudo:
Prognostic_studies
Limite:
Humans
/
Male
Idioma:
De
Ano de publicação:
2017
Tipo de documento:
Article